Short answer: Dr. Chadi Nabhan says yes: Ryght is building a platform where sites update their information and capabilities, such as interest in colorectal cancer trials, so they rank higher. He expects a press release within a couple of months.
Watch this answer from Episode 34 (starts at 15:58) · Episode 34 notes and transcript
From Episode 34: AI Is Rebuilding Clinical Trials, starting at 15:58.
Sam Nadler [15:58]: Yeah. No. Actually, I have one more question, if you don't mind. Like, I can and maybe this highlights my unfamiliarity with the space, but, I can totally see why CROs and sponsors are coming to you for the tool. Do sites themselves also who may be, less recognized and who want to do more of these kind of are they reaching out and saying, hey. Like, these are our capabilities. Like, how do we is is that something that happens?
Dr. Chadi Nabhan [16:25]: I think Sam should be working with us. I think he probably was think I think you were on our call last week or you called or something. The answer is absolutely yes. But as you know, Sam, I mean, we have just to be strategic and we have to think what we could do today versus the roadmap and so on, but absolutely we have a site strategy, and one of this is exactly what you said. There are so many sites out there that have certain capabilities that they could be forgotten because nobody really has reached out to them and know them. So we are building an entire platform for the sites where the sites actually go in and they're able to, a, update the information, tell us the information that they have because maybe they can add more information we cannot get. I mean, we can only get information that is available out there, but there are certain proprietary information that I may not be able to have unless the sites volunteer that, and we're building this. We're also connecting the sites with the sponsors to make sure that if a site I was having a conversation with a site just about last week, and they said, one of our interests is studies in colorectal cancer. And for whatever reason, we haven't had a lot of trials in colorectal cancer because the investigators that we have are not necessarily well known. We'd like to build their clinical trial portfolio.
Dr. Chadi Nabhan [17:50]: So a site like this would come to our platform and show that they have a lot of interest in colorectal cancer, they have capabilities, they just have not gotten the chance, and then they get ranked higher because we have that information and we're able to link. So the answer is a resounding yes, and that's actually happening. Hopefully by the next time we meet again, you'll see a lot of this progressing. I mean, this is very, very close actually where you're gonna hear about what we're doing on the side. I would say in less than a couple of months, you're gonna hear on a press release for that.
